Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Colorectal Cancer
Latest Information Update: 13 Sep 2022
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 07 Sep 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2024.
- 07 Sep 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2023.
- 07 Sep 2022 Status changed from recruiting to active, no longer recruiting.